Apart from the immunosuppressive character of tumor-derived ExVs, Li et al. [103] generated HER2-specific ExVs using polyclonal CD4+T cells prepared with ExVs released by HER2-specific DCs, and demonstrated their therapeutic effect against HER2-positive tumors in double-transgenic HER2/HLA-A2 mice with HER2-specific self-immune tolerance. Here, ERBB2 is linked to neoplasm.